PT  - JOURNAL ARTICLE
AU  - Kara K. Osbak
AU  - Achilleas Tsoumanis
AU  - Irith De Baetselier
AU  - Marjan Van Esbroek
AU  - Hilde Smet
AU  - Chris R. Kenyon
AU  - Tania Crucitti
TI  - The role of IgM testing in the diagnosis and post-treatment follow-up of syphilis: a prospective cohort study
AID  - 10.1101/19011148
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19011148
4099  - http://medrxiv.org/content/early/2019/11/14/19011148.short
4100  - http://medrxiv.org/content/early/2019/11/14/19011148.full
AB  - Objectives The diagnosis of repeat syphilis and its follow-up remains challenging. We aimed to investigate if IgM testing may assist in the diagnosis of syphilis reinfection/relapse and its treatment follow-up.Methods Sera were collected from 120 individuals with a new diagnosis of syphilis (72 with repeat infections) and 30 syphilis negative controls during a cohort study investigating syphilis biomarkers conducted at a STI/HIV clinic in Antwerp, Belgium. Syphilis was diagnosed based on a simultaneous positive treponemal and non-treponemal assay result and/or positive serum PCR targeting polA. Specimens collected at visit of diagnosis, and 3 and 6 months post-treatment were tested by two enzyme immuno assays (EIAs), recomWell (Mikrogen; MI) and Euroimmun (EU), to detect anti-treponemal IgM. Baseline specimens were also tested for anti-treponemal IgM using a line immuno assay (LIA) recomLine (Mikrogen). Quantitative kinetic decay curves were constructed from the longitudinal quantitative EIA results.Results An overall sensitivity for the diagnosis of syphilis of 59.8 % (95 % confidence interval (CI): 50.3-68.7), 75.0 % (95 %(CI): 66.1-82.3) and 64.2 % (95 %(CI): 54.8-72.6) was obtained for the EU, MI EIAs, and MI LIA, respectively. When only considering repeat syphilis, the diagnostic sensitivity decreased to 45.7 % (95 %(CI): 33.9-58.0), 63.9 % (95 %(CI): 51.7-74.6) and 47.2 % (95 %(CI): 35.5-59.3), respectively. IgM seroreverted in most cases 6 months after treatment. Post-treatment IgM concentrations decreased 30 % faster for initial syphilis compared to repeat infection. The IgM EIAs and IgM LIA agreed from fairly to moderately (Cohen’s kappa (κ): 0.36 [EU EIA]; κ: 0.53 [MI EIA]; κ: 0.40 [MI LIA]) with the diagnosis of syphilis.Conclusions IgM detection was not a sensitive method to diagnose syphilis and was even poorer in the diagnosis of syphilis repeat infections, but might play a role in treatment follow-up.KEY MESSAGE BOX- IgM detection was not a sensitive method to diagnose syphilis and was even poorer in the diagnosis of syphilis repeat infections- IgM serorevert in most cases 6 months after treatment- In repeat episodes of syphilis, IgM concentrations decline faster post-treatmentCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Nr: NCT02059525Funding StatementThis work was part of Project ID: 757003 funded by the Flemish Government-Department of Economy, Science & Innovation granted to CRK. The anti-Treponema pallidum IgM assays were provided free of charge by Euroimmun (Lübeck, Germany) and by Mikrogen GmbH (Neuried, Germany). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this publication are retained at the Institute of Tropical Medicine (ITM), Antwerp and will not be made openly accessible due to ethical and privacy concerns. According to the ITM research data sharing policy, only fully anonymised data can be shared publicly. The data are de-identified (using participant identification numbers only) but not fully anonymised and it is not possible to fully anonymise them due to the longitudinal nature of the data. Data can however be made available after approval of a motivated and written request to the ITM at ITM researchdataaccess{at}itg.be. The ITM data access committee will verify if the dataset is suitable for obtaining the study objective and assure that confidentiality and ethical requirements are in place.ARTAntiretroviral therapyRPRrapid plasma reagin card testNTTnon-treponemal testTTtreponemal testHIVHuman Immunodeficiency VirusITMInstitute Tropical Medicine-AntwerpMSMMen who have Sex with MenTPPATreponema pallidum passive particle agglutination testEIAenzyme immunoassayLIAline immunoassay